WVE - Wave Life Sciences Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.88
-0.23 (-2.84%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.11
Open8.11
Bid7.86 x 800
Ask8.28 x 3200
Day's Range7.84 - 8.13
52 Week Range7.22 - 48.64
Volume695,397
Avg. Volume873,598
Market Cap270.203M
Beta (5Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced topline data from the ongoing Phase 1b/2a PRECISION-HD2 trial evaluating investigational therapy WVE-120102, designed to be the first allele-selective approach to treat Huntington’s disease (HD). In an analysis comparing all patients treated with multiple intrathecal doses of WVE-120102 to placebo, a statistically significant reduction of 12.4% (p

  • GlobeNewswire

    Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study. As a result of this decision, the company is immediately discontinuing the two suvodirsen trials, the OLE study and the Phase 2/3 DYSTANCE 51 trial.

  • GlobeNewswire

    Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

    Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open-label extension study expected in 4Q 2019.

  • GlobeNewswire

    Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

    CAMBRIDGE, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) --  Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to suvodirsen for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 51 skipping. The designation was based on comprehensive in vitro and in vivo nonclinical data that support the potential for suvodirsen to address a significant unmet medical need.

  • GlobeNewswire

    Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

    CAMBRIDGE, Mass., Sept. 06, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.

  • GlobeNewswire

    Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., Aug. 26, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

  • GlobeNewswire

    Wave Life Sciences Appoints Mark Baldry as Chief Commercial Officer

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the appointment of Mark Baldry as Chief Commercial Officer. In this newly created position, Mr. Baldry will build and oversee Wave’s global commercial strategy and organization, including its sales, marketing and market access and reimbursement teams. Initially, he will focus on the launch planning for suvodirsen, the company’s investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

  • GlobeNewswire

    Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update

    Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated.

  • GlobeNewswire

    Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and safety clinical trial of suvodirsen, an investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. “The initiation of the DYSTANCE 51 Phase 2/3 study represents a significant milestone for Wave and our DMD clinical program, as well as an important development for the families affected by Duchenne,” said Michael Panzara, MD, MPH, Chief Medical Officer of Wave Life Sciences.

  • GlobeNewswire

    Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer

    Adaptimmune Therapeutics plc (ADAP) today announced that Adrian Rawcliffe, currently Chief Financial Officer (CFO) of the Company, will succeed James Noble as Chief Executive Officer (CEO). This transition will occur when James retires from his executive duties and transitions to a non-executive director role on the Company’s Board on September 1, 2019.

  • GlobeNewswire

    Wave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara, MD, MPH, Chief Medical Officer, will present at the Parent Project Muscular Dystrophy (PPMD) 2019 Annual Conference in Orlando, Fla. on Saturday, June 29, 2019 at 12:00 p.m. ET. The presentation will include an overview of the ongoing clinical development of suvodirsen, the company’s investigational stereopure oligonucleotide for boys with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Suvodirsen is currently being studied in an open label extension (OLE) study, initiated in August 2018 with patients from the Phase 1 clinical trial.

  • GlobeNewswire

    Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., May 10, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people.

  • GlobeNewswire

    Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the final results from its Phase 1 clinical trial of investigational suvodirsen (WVE-210201) in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. The company also announced the design of its planned Phase 2/3 clinical trial of suvodirsen in DMD, DYSTANCE 51.

  • GlobeNewswire

    Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference

    Suvodirsen Phase 1 Safety and Tolerability Results Accepted for Oral Presentation Investor Conference Call and Webcast Scheduled for Tuesday, April 16 CAMBRIDGE, Mass., April.

  • GlobeNewswire

    Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today provided an update on the timing of the topline data readout from its ongoing PRECISION-HD program, which consists of two global Phase 1b/2a clinical trials evaluating investigational therapies WVE-120101 and WVE-120102 for patients with Huntington’s disease (HD). The company now expects to report topline clinical data from the PRECISION-HD program by the end of the year. This update is not due to a preclinical or clinical safety finding and the PRECISION-HD clinical program remains blinded.

  • GlobeNewswire

    Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference

    Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and progress for its Duchenne muscular dystrophy (DMD) programs will be shared at the 2019 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference themed, “Progress in Motion,” April 13-17, 2019 in Orlando, Fla. This year the MDA annual conference will gather both healthcare providers and researchers together into one conference to discuss the latest in neuromuscular disease research and care.

  • GlobeNewswire

    Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference

    CAMBRIDGE, Mass., March 06, 2019 -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.

  • GlobeNewswire

    Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., March 01, 2019 -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for.

  • GlobeNewswire

    Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence

    NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
    PR Newswire

    Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

    Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs ...

  • GlobeNewswire

    Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

    Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten public offering of 3,950,000 of its ordinary shares at a price to the public of $38.00 per ordinary share. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 592,500 of its ordinary shares on the same terms and conditions.

  • GlobeNewswire

    Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

    Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of its ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering on the same terms and conditions. All of the shares in the offering will be sold by Wave Life Sciences.